ACAD Stock Analysis: ACADIA Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.438m USD | 12M Return: -8.6% | US0042251084 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 49.3M
Qual. Beats: 0
Rev. Trend: 94.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ACADIA Pharmaceuticals is a San Diego-based biopharmaceutical company that develops and commercializes treatments for neurological and rare diseases, primarily in North America. The company markets two products: NUPLAZID, approved for hallucinations and delusions associated with Parkinsons disease psychosis, and DAYBUE, approved for Rett syndrome. Its clinical pipeline includes Phase 2 candidates for Alzheimers disease psychosis, Lewy body dementia psychosis, major depressive disorder, and Phase 1 programs for essential tremor, tardive dyskinesia, Huntingtons disease, Rett syndrome, and fragile X syndrome, along with a discovery-stage antisense oligonucleotide program for SYNGAP1 syndrome. ACADIA holds license agreements with Neuren Pharmaceuticals for trofinetide and a collaboration with Stoke Therapeutics for RNA-based medicines targeting severe neurodevelopmental CNS diseases.
As a mid-cap biotechnology firm, ACADIA operates a pipeline-driven business model where revenue concentration in two marketed products is balanced by ongoing clinical development across multiple neurology indications. Rare disease and specialty neurology drugs in the U.S. market often benefit from FDA orphan drug designation, which can provide extended market exclusivity and influence pricing dynamics.
- NUPLAZID revenue growth drives Parkinsons psychosis market share
- DAYBUE uptake in Rett syndrome accelerates top-line expansion
- Phase 2 Alzheimers psychosis data readout catalysts pipeline value
| Net Income: 380.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -5.26 > 1.0 |
| NWC/Revenue: 75.80% < 20% (prev 61.88%; Δ 13.92% < -1%) |
| CFO/TA 0.11 > 3% & CFO 194.3m > Net Income 380.5m |
| Net Debt (-882.6m) to EBITDA (116.1m): -7.60 < 3 |
| Current Ratio: 3.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.9m) vs 12m ago 2.47% < -2% |
| Gross Margin: 91.13% > 18% (prev 91.97%; Δ -0.84% > 0.5%) |
| Asset Turnover: 76.72% > 50% (prev 83.14%; Δ -6.42% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.50 (Total Current Assets 1.22b - Total Current Liabilities 361.4m) / Total Assets 1.74b |
| B: -1.02 (Retained Earnings -1.78b / Total Assets 1.74b) |
| C: 0.07 (EBIT TTM 104.1m / Avg Total Assets 1.48b) |
| D: 2.99 (Book Value of Equity 1.31b / Total Liabilities 436.3m) |
| Altman-Z'' = 3.54 = A |
| DSRI: 1.24 (Receivables 166.3m/119.7m, Revenue 1.14b/1.02b) |
| GMI: 1.01 (GM 91.97% / 91.13%) |
| AQI: 1.44 (AQ_t 0.25 / AQ_t-1 0.17) |
| SGI: 1.12 (Revenue 1.14b / 1.02b) |
| TATA: 0.11 (NI 380.5m - CFO 194.3m) / TA 1.74b) |
| Beneish M = -2.46 (Cap -4..+1) = BBB |
As of October 07, 2026, the stock is trading at USD 19.74 with a total of 1,665,697 shares traded. Over the past week, the price has changed by -2.37%, over one month by -28.43%, over three months by -23.40% and over the past year by -8.57%.
Current recommended Stop Loss: 18.60 (which is 5.8% or 1.2 ATR below the current price).
ACADIA Pharmaceuticals has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy ACAD.
- StrongBuy: 11
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 32.2 | 62.9% |
P/E Trailing = 8.9462
P/E Forward = 25.1889
P/S = 3.0189
P/B = 3.3509
P/EG = 50.8642
Revenue TTM = 1.14b USD
EBIT TTM = 104.1m USD
EBITDA TTM = 116.1m USD
Long Term Debt = 59.5m USD (estimated: total debt 73.9m - short term 14.3m)
Short Term Debt = 14.3m USD (from shortTermDebt, last quarter)
Debt = 73.9m USD (from shortLongTermDebtTotal, last quarter) (leases 73.9m already included)
Net Debt = -882.6m USD (calculated: Debt 73.9m - CCE 956.5m)
Enterprise Value = 2.55b USD (3.44b + Debt 73.9m - CCE 956.5m)
Interest Coverage Ratio = unknown (Ebit TTM 104.1m / Interest Expense TTM 0.0)
EV/FCF = 14.65x (Enterprise Value 2.55b / FCF TTM 174.4m)
FCF Yield = 6.83% (FCF TTM 174.4m / Enterprise Value 2.55b)
FCF Margin = 15.32% (FCF TTM 174.4m / Revenue TTM 1.14b)
Net Margin = 33.42% (Net Income TTM 380.5m / Revenue TTM 1.14b)
Gross Margin = 91.13% ((Revenue TTM 1.14b - Cost of Revenue TTM 101.0m) / Revenue TTM)
Gross Margin QoQ = 90.81% (prev 90.75%)
Tobins Q-Ratio = 1.47 (Enterprise Value 2.55b / Total Assets 1.74b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 73.9m)
Taxrate = 32.22% (15.0m / 46.5m)
NOPAT = 70.6m (EBIT 104.1m * (1 - 32.22%))
Current Ratio = 3.39 (Total Current Assets 1.22b / Total Current Liabilities 361.4m)
Debt / Equity = 0.06 (Debt 73.9m / totalStockholderEquity, last quarter 1.31b)
Debt / EBITDA = -7.60 (Net Debt -882.6m / EBITDA 116.1m)
Debt / FCF = -5.06 (Net Debt -882.6m / FCF TTM 174.4m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 25.64% (Net Income 380.5m / Total Assets 1.74b)
RoE = 32.39% (Net Income TTM 380.5m / Total Stockholder Equity 1.17b)
RoCE = 8.43% (EBIT 104.1m / Capital Employed (Equity 1.17b + L.T.Debt 59.5m))
RoIC = 5.27% (NOPAT 70.6m / Invested Capital 1.34b)
WACC = 9.30% (E(3.44b)/V(3.51b) * Re(9.50%) + D(73.9m)/V(3.51b) * Rd(0.0%) * (1-Tc(0.32)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.04 | Cagr: 1.64%
[DCF] Terminal Value 71.11% ; FCFF base≈179.5m ; Y1≈170.0m ; Y5≈160.2m
[DCF] Fair Price = 17.75 (EV 2.18b - Net Debt -882.6m = Equity 3.06b / Shares 172.3m; r=9.30% [WACC]; 5y FCF grow -6.78% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.53 | # QB: 0
Revenue Correlation: 94.02 | Revenue CAGR: 20.32% | SUE: 1.57 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.19 | Chg30d=+0.00% | Revisions=+77% | Analysts=14
EPS current Year (2026-12-31): EPS=0.60 | Chg30d=+0.00% | Revisions=+81% | GrowthEPS=-27.8% | GrowthRev=+18.8%
EPS next Year (2027-12-31): EPS=0.89 | Chg30d=-0.17% | Revisions=-25% | GrowthEPS=+48.2% | GrowthRev=+12.6%
[Analyst] Revisions Ratio: +81% (up=23, down=1)